Penpulimab联合化疗用于可切除HNSCC患者的新辅助和辅助治疗
Penpulimab联合化疗用于可切除头颈鳞状细胞癌新辅助及辅助治疗的II期临床研究
This study aims to observe and explore the efficacy and safety of Penpulimab combined with chemotherapy for neoadjuvant and adjuvant therapy in patients with resectable head and neck squamous cell carcinoma.
研究概览
研究类型
注册 (估计的)
阶段
- 阶段2
联系人和位置
学习地点
-
-
Shanghai Municipality
-
Shanghai、Shanghai Municipality、中国、200011
- Shanghai Ninth People's Hostipal, Shanghai Jiao Tong University School of Medicine
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
- Patients voluntarily joined the study, signed the informed consent, and had good compliance;
- Patients with 18 Years to 75 Years(at the time of signing the informed consent); Eastern Cooperative Oncology Group Performance Status (ECOG-PS) score: 0-1;
- Patients with untreated head and neck squamous cell carcinoma who were pathologically confirmed and determined to be suitable for surgical treatment were classified as stage III, IVa according to AJCC (8th Edition), including oral, oropharyngeal, hypopharyngeal, and laryngeal cancers
- Female patients of reproductive age should agree that birth control (such as intrauterine device, birth control pills, or condoms) must be used during the study period and for six months after completion; Having a negative serum pregnancy test within 7 days prior to study enrollment, and must be non-lactating; Male patients should agree to use contraception during the study period and for six months after the end of the study.
Exclusion Criteria:
- Patients who have previously used PD-1/PD-L1/CTLA-4 antibody therapy;
- Patients who require systemic treatment with corticosteroids (> 10mg daily prednisone equivalent) or other immunosuppressive drugs within 14 days prior to administration or during treatmentIn the absence of active autoimmune disease, inhaled or topical steroids and adrenocortical hormone at doses >10mg/ day equivalent to prednisone and adrenocortical hormone replacement at therapeutic doses not exceeding 10mg/ day prednisone are permitted;
- A history of any active immune or autoimmune disease, or a known history of allogeneic organ transplantation or allogeneic hematopoietic stem cell transplantation;
- Active or uncontrolled severe infection within 4 weeks prior to enrollment (CTCAE grade 2 infection);
- Abnormal function of major organs
- Patients with concomitant diseases that, in the investigator's judgment, may seriously endanger patients' safety or may interfere with the completion of the study, or are deemed unsuitable for inclusion for other reasons.
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:不适用
- 介入模型:单组作业
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:Penpulimab combined with cisplatin and albumin-paclitaxel neoadjuvant therapy
Penpulimab injection combined with cis-platinum and albumin-bound paclitaxel before surgery, 21 days as a treatment cycle. Adjuvant therapy was started within 6 weeks after surgery:Patients who achieved MPR after surgery were randomized 1:1 with standard adjuvant therapy(RT alone or combined with cisplatin) and Alternative adjuvant therapy(RT alone or combined with Penpulimab). Non-MPR patients receive standard adjuvant therapy |
Penpulimab is a human immunoglobulin G1(IgG1) monoclonal antibody (mAb) directly programmed cell death-1 (PD-1). AK105 can effectively prevent human PD-1 binds to programmed cell death-1 ligand 1(PD-L1) and programmed cell death-1 ligand 2(PD-L2); 200mg,D1, IV(21 days/cycle). Cisplatin :75mg/m2, D1, IV(21 days/cycle) albumin-paclitaxel :260mg/m2,IVgtt,D1(21 days/cycle) |
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Major pathological response(MPR)
大体时间:One year
|
Major pathologic response is based on the pathological examination on the post-operative specimens. |
One year
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Disease-control Rate(DCR)
大体时间:Baseline up to 3 years.
|
The proportion of subjects response of CR, PR, or SD (subjects achieving SD will be included in the DCR if they maintain SD for ≥4 weeks). |
Baseline up to 3 years.
|
|
Adverse event rate
大体时间:Baseline up to 3 years.
|
The occurrence of all adverse events (AEs), serious adverse events (SAEs) and treatment-related adverse events (TEAEs). |
Baseline up to 3 years.
|
|
Disease-free survival at 2 years(DFS at 2 years)
大体时间:Baseline up to 2 years.
|
The proportion of subjects disease-free survival at 2 years |
Baseline up to 2 years.
|
|
Overall Response Rate (ORR)
大体时间:Baseline up to 3 years.
|
The proportion of subjects who achieves a best overall response of CR or PR. |
Baseline up to 3 years.
|
|
Local recurrence-free survival at 2years(LRFS at 2 years)
大体时间:Baseline up to 2 years.
|
The proportion of subjects local recurrence-free survival at 2years |
Baseline up to 2 years.
|
|
distant metastasis-free survival at 2 years(DMFS at 2 years)
大体时间:Baseline up to 2 years.
|
The proportion of subjects distant metastasis-free survival at 2years |
Baseline up to 2 years.
|
|
OS at 2 years
大体时间:Baseline up to 2 years.
|
The overall survival time refers to the time from initiating inductive therapy to death due to any cause. |
Baseline up to 2 years.
|
|
pathologic complete response(pCR)
大体时间:One year
|
Pathological examination showed the presence of 0% active tumor in the tissue specimen |
One year
|
合作者和调查者
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.